In that study the incidence of fatal thromboembolic events was higher in patients receiving epoetin alfa than in those receiving placebo (see section 5.1).
I det forsøg var incidensen af fatale tromboemboliske hændelser højere hos patienter, som fik epoetin alfa end hos placebogruppen (se afsnit 5. 1).